Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3910 |
Name | lung adenocarcinoma |
Definition | A lung non-small cell carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4826 DOID:3909 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MAP2K1 K57N | Selumetinib | lung adenocarcinoma | sensitive | detail... |
PIK3CA H1047R | Dactolisib | lung adenocarcinoma | sensitive | detail... |
PIK3CA H1047R | Sirolimus | lung adenocarcinoma | no benefit | detail... |
FBXW7 R465H | Temsirolimus | lung adenocarcinoma | sensitive | detail... |
FGFR3 - TACC3 | Ponatinib | lung adenocarcinoma | sensitive | detail... |
FGFR3 - TACC3 | Infigratinib | lung adenocarcinoma | sensitive | detail... |
ROS1 rearrange | Crizotinib | lung adenocarcinoma | sensitive | detail... |
ERBB2 mutant | Afatinib | lung adenocarcinoma | sensitive | detail... |
ALK rearrange ALK I1171T | Alectinib | lung adenocarcinoma | resistant | detail... |
ALK rearrange ALK I1171T | Crizotinib | lung adenocarcinoma | resistant | detail... |
Unknown unknown | Nintedanib | lung adenocarcinoma | not applicable | detail... |
MAP2K1 Q56P | Trametinib | lung adenocarcinoma | sensitive | detail... |
MAP2K1 Q56P | Selumetinib | lung adenocarcinoma | sensitive | detail... |
MAP2K1 Q56P | Refametinib | lung adenocarcinoma | sensitive | detail... |
MAP2K1 Q56P | PD-0325901 | lung adenocarcinoma | sensitive | detail... |
BRAF mutant | Trametinib | lung adenocarcinoma | sensitive | detail... |
NRAS mutant | Trametinib | lung adenocarcinoma | resistant | detail... |
ABL1 R332W | Imatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 G321L | Imatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 T315I ABL1 R332W | Imatinib | lung adenocarcinoma | resistant | detail... |
ABL1 R332W | Dasatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 G321L | Dasatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 T315I ABL1 R332W | Dasatinib | lung adenocarcinoma | resistant | detail... |
IDH1 mutant | Dasatinib | lung adenocarcinoma | resistant | detail... |
ERBB2 exon 20 ins | Afatinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 Y772_A775dup | Afatinib | lung adenocarcinoma | no benefit | detail... |
ERBB2 G778_P780dup | Afatinib | lung adenocarcinoma | predicted - sensitive | detail... |
FGFR1 positive | AZD4547 + AZD8055 | lung adenocarcinoma | sensitive | detail... |
FGFR1 positive | AZD4547 + Vistusertib | lung adenocarcinoma | sensitive | detail... |
FGFR1 positive | AZD4547 + Sirolimus | lung adenocarcinoma | sensitive | detail... |
BRAF G469L | Vemurafenib | lung adenocarcinoma | no benefit | detail... |
BRAF N581S | PF-00477736 + PF3644022 | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 L869R | Lapatinib | lung adenocarcinoma | predicted - resistant | detail... |
ERBB2 M774delinsWLV | Dacomitinib | lung adenocarcinoma | sensitive | detail... |
ERBB2 G778_P780dup | Dacomitinib | lung adenocarcinoma | sensitive | detail... |
AKT1 E17K | Capivasertib | lung adenocarcinoma | predicted - sensitive | detail... |
Unknown unknown | Docetaxel + Nintedanib | lung adenocarcinoma | not applicable | detail... |
FGFR3 positive | Rogaratinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G469A | PLX8394 | lung adenocarcinoma | sensitive | detail... |
BRAF G466V | PLX8394 | lung adenocarcinoma | sensitive | detail... |
BRAF V600E BRAF amp | SCH772984 | lung adenocarcinoma | decreased response | detail... |
BRAF V600E BRAF amp | Dabrafenib + SCH772984 + Trametinib | lung adenocarcinoma | sensitive | detail... |
ALK rearrange ALK G1123S | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1123S | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1196M | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
FGFR1 amp | PRN1371 | lung adenocarcinoma | sensitive | detail... |
Unknown unknown | AC-93253 iodide + Gefitinib | lung adenocarcinoma | not applicable | detail... |
Unknown unknown | JNJ-64041757 | lung adenocarcinoma | not applicable | detail... |
RET V804M RET M918T | Alectinib | lung adenocarcinoma | resistant | detail... |
BRAF V600E NRAS Q61K | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - resistant | detail... |
ERBB2 exon 20 ins | Dacomitinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 amp | Dacomitinib | lung adenocarcinoma | no benefit | detail... |
ERBB2 G776delinsVC | Poziotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 Y772_A775dup | Poziotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 E812K | Poziotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 N813D | Afatinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 act mut | Ado-trastuzumab emtansine | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G778_P780dup | Ado-trastuzumab emtansine | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G776delinsVC | Ado-trastuzumab emtansine | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 V659E | Ado-trastuzumab emtansine | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 S310F ERBB2 amp | Ado-trastuzumab emtansine | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1152R | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1152R | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196M | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK G1269A | Belizatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK D1203N ALK G1269A | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1256F | Lorlatinib | lung adenocarcinoma | resistant | detail... |
EML4 - ALK ALK L1256F | Alectinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK T1151K | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK T1151K | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1196M | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M ALK D1203N | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M ALK D1203N | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Lorlatinib | lung adenocarcinoma | unknown | detail... |
ALK rearrange ALK C1156Y | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Lorlatinib + Saracatinib | lung adenocarcinoma | sensitive | detail... |
ALK rearrange ALK C1156Y | Lorlatinib + Saracatinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK G1202R | Brigatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK T1151M ALK C1156Y ALK F1174L ALK G1202R ALK S1206F ALK G1269A | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1269A | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
RET rearrange | Cabozantinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G776delinsVC | Afatinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 V777L | Afatinib | lung adenocarcinoma | predicted - sensitive | detail... |
Unknown unknown | ORCA-010 | lung adenocarcinoma | not applicable | detail... |
BRAF G464V | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF G466A | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF D594G | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF N581S | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF G466V | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF G469A | Trametinib | lung adenocarcinoma | no benefit | detail... |
ERBB2 L755P | Ado-trastuzumab emtansine | lung adenocarcinoma | no benefit | detail... |
ERBB2 G778_S779insCPG | Ado-trastuzumab emtansine | lung adenocarcinoma | no benefit | detail... |
ERBB2 act mut | Trastuzumab deruxtecan | lung adenocarcinoma | sensitive | detail... |
ERBB2 G778_P780dup | Poziotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G778_P780dup | Pyrotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G778_P780dup ERBB2 amp | Pyrotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G778_P780dup ERBB2 amp | Dacomitinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G778_P780dup | Afatinib + Cisplatin + Pemetrexed Disodium | lung adenocarcinoma | predicted - sensitive | detail... |
CDKN2A loss | Palbociclib | lung adenocarcinoma | predicted - sensitive | detail... |
PIK3CA mutant | Capivasertib | lung adenocarcinoma | no benefit | detail... |
AKT1 mutant | Capivasertib | lung adenocarcinoma | no benefit | detail... |
EML4 - ALK | Lorlatinib | lung adenocarcinoma | conflicting | detail... |
EML4 - ALK | Alvocidib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK | Dinaciclib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK | Alvocidib + Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | THZ1 | lung adenocarcinoma | sensitive | detail... |
ALK rearrange | CT-707 | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 G778_S779insCPG | Bevacizumab + Pyrotinib | lung adenocarcinoma | predicted - sensitive | detail... |
STK11 mutant | unspecified PD-1 antibody | lung adenocarcinoma | not predictive | detail... |
STK11 mutant | unspecified PD-L1 antibody | lung adenocarcinoma | not predictive | detail... |
STK11 mutant | N/A | lung adenocarcinoma | not applicable | detail... |
BRAF V600E | Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange | Bevacizumab + Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
ERBB2 Y772_A775dup | Ado-trastuzumab emtansine | lung adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01579994 | Phase I | Crizotinib + Ganetespib | Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | Completed | USA | 0 |
NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01814553 | Phase III | Afatinib + Loperamide | ADAM-Afatinib Diarrhea Assessment and Management | Completed | USA | 0 |
NCT01877083 | Phase II | Lenvatinib | Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | Completed | USA | 4 |
NCT01877811 | Phase Ib/II | RXDX-105 | CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 | Completed | USA | 0 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | 6 |
NCT02185690 | Phase I | Binimetinib + Carboplatin + Pemetrexed Disodium | A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | Active, not recruiting | CAN | 0 |
NCT02231164 | Phase III | Docetaxel Nintedanib | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | Terminated | USA | 2 |
NCT02264678 | Phase Ib/II | AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | 3 |
NCT02285855 | Phase II | Metformin | Metformin in Non Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT02450175 | Phase I | Letrozole Everolimus | Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | Unknown status | USA | 0 |
NCT02450591 | Phase I | Erlotinib | Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations | Completed | USA | 0 |
NCT02466568 | Phase Ib/II | Nivolumab | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Withdrawn | 0 | |
NCT02503358 | Phase I | Paclitaxel + Selumetinib | Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02513667 | Phase II | Ceritinib | Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02705339 | Phase II | Rociletinib | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 0 | |
NCT02759835 | Phase II | Osimertinib | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | Active, not recruiting | USA | 0 |
NCT02839681 | Phase II | Anetumab ravtansine | Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma | Terminated | USA | 0 |
NCT02864992 | Phase II | Tepotinib | Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (VISION) | Recruiting | USA | 14 |
NCT03076164 | Phase Ib/II | Erlotinib + Trametinib | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | Completed | USA | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Active, not recruiting | USA | CAN | 10 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Active, not recruiting | 1 | |
NCT03371381 | Phase Ib/II | JNJ-64041757 + Nivolumab Nivolumab | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | Terminated | USA | 2 |
NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
NCT03696212 | Phase Ib/II | Grapiprant + Pembrolizumab | Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | Terminated | USA | 0 |
NCT03704688 | Phase Ib/II | Ponatinib + Trametinib | Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | USA | CAN | 2 |
NCT03944772 | Phase II | Necitumumab + Osimertinib Osimertinib + Selpercatinib Alectinib + Osimertinib Carboplatin + Durvalumab + Pemetrexed Disodium Osimertinib + Savolitinib Gefitinib + Osimertinib | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD) | Recruiting | USA | 7 |
NCT04145622 | Phase Ib/II | DS-7300a | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04180371 | Phase Ib/II | BT5528 + Nivolumab BT5528 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Recruiting | USA | 1 |
NCT04263090 | Phase Ib/II | Nivolumab + Rigosertib | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Recruiting | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Recruiting | USA | 3 |
NCT04545710 | Phase II | Abemaciclib + Osimertinib | Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance | Recruiting | USA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) | Recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |